MaaT Pharma plans late-2027 first-in-human trial of MaaT034 with PD-(L)1 inhibitors in solid tumors

By Public Technologies
  • MaaT Pharma set an FDA pre-IND meeting for October 2026 to advance MaaT034 into clinical development, with emphasis on manufacturing controls.
  • Preclinical results were already presented at AACR and SITC meetings, supporting plans to move into human testing.
  • A first-in-human study was designed to establish dosing and generate early proof-of-concept in solid tumors alongside PD-(L)1 inhibitors.
  • Initial targets include second-line advanced NSCLC and refractory advanced melanoma, aiming to improve response to immunotherapy in resistant disease.
  • Trial start is projected for late 2027, contingent on funding and regulatory clearance.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maat Pharma SA published the original content used to generate this news brief via Business Wire (Ref. ID: 202609211300BIZWIRE_USPR_____20260921_BW576057) on September 21, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.